✦ LIBER ✦

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma

✍ Scribed by D.I Jodrell; T.R.J Evans; W Steward; D Cameron; J Prendiville; C Aschele; C Noberasco; M Lind; J Carmichael; N Dobbs; G Camboni; B Gatti; F De Braud

Book ID: 116428233
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 165 KB
Volume: 40
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2004.04.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical study of BBR 3464, a n

Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer

✍ A.H. Calvert; H. Thomas; N. Colombo; M. Gore; H. Earl; L. Sena; G. Camboni; P. L 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Phase II study of cetuximab in combinati

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)

✍ Pinto, C; Di Fabio, F; Barone, C; Siena, S; Falcone, A; Cascinu, S; Rojas Llimpe 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 341 KB

A phase II open-label study of DHA-pacli

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

✍ Robert J. Jones; Robert E. Hawkins; Martin M. Eatock; David R. Ferry; Ferry A. L 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 265 KB

A phase II trial of the Src kinase inhib

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

✍ Helen J. Mackay, Heather J. Au, Elaine McWhirter, Thierry Alcindor, Andrea Jarvi 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 116 KB

Phase II study of sequential cisplatin p

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

✍ Fotios Loupakis; Gianluca Masi; Lorenzo Fornaro; Enrico Vasile; Giacomo Allegrin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 233 KB